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Promoting Myocardial Recovery With Ventricular Assist Device*Hao A. Tran, MD, Jorge Silva Enciso, MD, Eric D. Adler, MDSEE PAGE 1602V entricular assist devices (VADs) have funda-mentally changed the treatment of end-stage heart failure. However, despite great
advances, long-term VAD use is still associated with
frequent hospitalizations, serious complications,
and a 2-year survival of approximately 70% (1).
Although myocardial recovery has long been touted
as the holy grail of mechanical circulatory support,
true myocardial recovery, in which function returns
to normal, is unfortunately akin to urban legend:
often discussed but seldom seen. According to the
Interagency Registry for Mechanically Assisted Circu-
latory Support, functional recovery leading to explant
occurs in <1% of cases in the United States in a select
group of patients (2).
As a maladaptive response, myocardial remodeling
driven by ventricular pressure and volume over-
load has been implicated in progressive myocardial
dysfunction in heart failure (3). In theory, mechani-
cally venting the overloaded left ventricle (LV) should
promote recovery. Previous studies demonstrated
some degree of “reverse remodeling” in subsets of
patients on left ventricular assist device (LVAD) sup-
port (4–7). This new ﬁeld of VAD research has opened
the gateway to investigative efforts and collabora-
tions in this age of regenerative medicine. However,
myocardial recovery research has shown conﬂicting
results that are difﬁcult to replicate in clinical practice
(differences in patient selection, type of heart failure,
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disclose.has been shown to be superior over another. Studies
of patients on mechanical circulatory support evalu-
ated with serial echocardiography and invasive he-
modynamics demonstrated a relative improvement
in LV systolic function, a decrease in intraventricular
dimension indices (LV end-diastolic and end-systolic
volume), and an improvement in diastolic parame-
ters after VAD implantation (7,8). However, limited
data correlating the direct effect of mechanical
unloading with myocyte function, myocardial endo-
thelium, and microvasculature are available. Previous
studies illustrated regression of hypertrophy and
even cardiac myocyte atrophy (9,10). Although in-
creased microvascular density, increased ﬁbrosis, and
reduced cardiomyocyte hypertrophy after mechanical
unloading of the left ventricle were noted, ultra-
structural and metabolic evidence of degeneration or
atrophy were absent (11). Atrophy with LVAD has long
been speculated as an explanation for why the me-
chanically supported heart rarely recovers. It has
been hypothesized that, much like a muscle in a cast,
unloading a ventricle with a VAD results in sarcomeric
degeneration and impairs recovery.In this issue of the Journal, Diakos et al. (12) assess
myocardial atrophy in patients undergoing LVAD im-
plantation. In this single-center prospective study, 44
patients with continuous-ﬂow LVAD support as a
bridge to transplantation had myocardial tissue eval-
uated pre- and post-implant (12). Pre-LVAD tissue
samples were obtained from the LV apical core at
the time of implant, and pre-transplant tissue samples
were collected at the time of explant at a pre-
determined distance from the LVAD inﬂow cannula
site. Donor hearts not allocated for heart transplant
for noncardiac reasons were used as a control arm.
Microscopic analysis revealed signiﬁcant reductions in
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1614cardiomyocyte cross-sectional area and LV mass after
LVADunloading, but not beyond that of normal control
hearts. The authors suggested that this represented
reverse remodeling that did not regress to the point
of atrophy. Additionally, serial echocardiographic
studies did not show any structural or functional evi-
dence compatible with myocardial atrophy. Ultra-
structural analysis by electron microscopy did not
reveal evidence of LVAD-induced atrophic changes.
Finally, microstructural and metabolic changes asso-
ciated with atrophic myocardium (increased glycogen
content, disarrayed distribution of t-tubules and
ryanodine receptor clusters, and excessive protein
degradation) were not enhanced in post-LVAD un-
loading. Furthermore, after 6 months of mechanical
support, a subgroup of patients in the present study
demonstrated improvements in LV dimension and
volume indexes and no evidence of signiﬁcant atrophy
by way of ultrastructural atrophy score, ryanodine re-
ceptor distance, myocardial glycogen content, or up-
regulation of proteolytic pathways.
Although these structural and metabolic ﬁndings
move the ﬁeld forward, the discordance between
functional myocardial improvement and clinical
outcomes is 1 of the challenges addressing the sus-
tainability of myocardial recovery (13). Furthermore,
prior studies demonstrated that normalizing LV he-
modynamics by LVAD therapy ameliorates the
neurohormonal disarray seen in the failing heart and
improves cardiomyocyte contractile properties by
increasing beta-adrenergic responsiveness (14,15).
However, the current study did not evaluate theadrenergic response to the mechanical assist device;
thus, causality between the neurohormonal axis and
microvascular changes cannot be commented upon. It
may also still be too premature to exalt microvascular
improvement as a surrogate marker indicating suit-
able functional changes acceptable for device
explantation.
The authors should be lauded for their continued
trailblazing work in the investigation of myocardial
recovery after left ventricular unloading in failing
hearts. Nevertheless, through the exhaustive gauntlet
of functional, microvascular, and ultrastructural pa-
rameters reported in 2 separate excellent papers, 1
question still lingers: what is required for sustained
clinical LV recovery? Though VADs may create a
permissive milieu for recovery, mechanical unloading
alone is clearly not enough. There is currently little
consensus on how to identify patients with the ability
to recovery, which VAD settings promote recovery, or
even whether or not neurohormonal therapy is indi-
cated in this patient population. A wide variety of
studies are underway, including preliminary work
using stem cells and gene therapy in conjunction with
VADs. Clearly, more work like that of Diakos et al. (12)
will be required before VADs reach their full potential
as a therapy that treats, rather than simply supports,
the failing heart.
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